Shots:

• Aurigene to fund and conduct P-IIb/III study assessing CA-170 + chemoradiation in ~240 patients with nsq. NSCLC and get exclusive rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia- as per its previous agreement
• Curis will retain the right to develop & commercialize CA-170 in the US- EU and ROW and will receive royalties on sales of the therapy in Asia
• CA-170 (PO) is a dual inhibitor of VISTA and PDL1- being evaluated in P-IIa basket study- demonstrated efficacy in patients with nsq. NSCLC

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Just Dial